The TEC Edmonton incubator and Genzyme Canada have come together in a strategic partnership to launch the TEC Health Accelerator program. The goal is to accelerate the growth of Alberta biotech companies and connect entrepreneurs with medical and scientific researchers in Alberta, with the hopes of also attracting investors to fund healthcare projects.
Genzyme Canada, a division of Sanofi-aventis Canada, has been in business for over 30-years, with expertise in rare genetic diseases known as lysosomal storage disorders (LSDs) and multiple sclerosis.
“Genzyme brings the resources of one of the world’s largest pharmaceutical companies to support TEC Edmonton,” said Chris Lumb, CEO of TEC Edmonton. “This means greater opportunities for clients in the Alberta healthcare industry to grow faster by accessing the expertise of a high quality industry partner and who could potentially be a commercialization partner for new drug and diagnostic inventions.”
”Collaboration and partnership are core values at Genzyme,” said Peter Brenders, General Manager of Genzyme Canada. “We look forward to this opportunity to work with TEC Edmonton, the government of Alberta, and Alberta’s biotech companies and community of researchers to develop new innovations in healthcare.”